Browse EX-10 agreements

EMPLOYMENT AGREEMENT

EMPLOYMENT AGREEMENT (“Agreement”), dated as of July 3, 2026, between PVH CORP., a Delaware corporation (“PVH” and, together with its affiliates and subsidiaries, the “Company”), and ALEXIS ROLLIER (the “Executive”).

W I T N E S S E T H:

WHEREAS, the Company desires to retain the Executive on a full-time basis in accordance with the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants herein contained, the parties hereto hereby agree as follows:

1. Employment.

…

**Certain identified information marked as [****] has been excluded from this exhibit because it both (i) is not material and (ii) is the type that the Company treats as private or confidential. **

**MANUFACTURING AND SUPPLY AGREEMENT **

This *Manufacturing and Supply Agreement ***(“Agreement”) **is entered into as of the as of the date of the last signature below (the “Effective Date”) between:

(i) Alivus Life Sciences Limited (formerly known as Glenmark Life Sciences Limited), a company incorporated under the laws of India and having its registered office at Plot No 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth Solapur-413 213, MH, India and having its corporate office at Technopolis Knowledge Park, A Wing, Office no. 401 to 407, 4thFloor, Mahakali Caves Road, Andheri (E), Mumbai 400093, India, India, **(“Alivus”); **and

…

REPAY HOLDINGS CORPORATION

July 13, 2026

This agreement (the “Cooperation Agreement”) memorializes the understandings and agreements that Repay Holdings Corporation (the “Company”) and PCP Managers II, L.P. (the “Investor Party”) have reached relating to, among other things, the appointment of Zach Sadek to the Company’s Board of Directors (the “Board”).

The Company and the Investor Party have successfully reached the following agreements:

1.

In accordance with the Company’s organizational documentsand applicable law, the Company agrees that the Board and each applicable committee of the Board shall take all actions necessary to, in each case, subject to Section 2:

(a)

as promptly as practicable following the date hereof, increase the size of the Board from six (6) to seven (7) members;

(b)

…

SECURITIES PURCHASE AGREEMENT

** **

This **SECURITIES PURCHASE AGREEMENT **(the “Agreement”), dated as of July 8, 2026, by and between Edgemode, Inc., a Nevada corporation, with its address at 110 E. Broward Blvd., Suite 1700, Ft. Lauderdale, FL 33301 (the “Company”), and Vanquish Funding Group Inc., a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, Alexandria VA 22314 (the “Buyer”).

WHEREAS:

A.The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “1933 Act”); and

B.Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement, a promissory note of the Company, in the form attached hereto as Exhibit A, in the aggregate principal amount of $129,600.00 (including $21,600.00 of Original Issue Discount) (the “Note”).

…

THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT.

** **

THE ISSUE PRICE OF THIS NOTE IS $129,600.00

THE ORIGINAL ISSUE DISCOUNT IS $21,600.00

** **

Principal Amount: $129,600.00	Issue Date: July 8, 2026
Purchase Price: $108,000.00

** **

PROMISSORY NOTE

** **

…

**Execution **

**FIFTH AMENDMENT TO **

**SECOND AMENDED AND RESTATED CREDIT AGREEMENT **

THIS FIFTH AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) is entered into as of July 14, 2026 (the “Effective Date”), by and among WELLS FARGO CAPITAL FINANCE, LLC, a Delaware limited liability company, as the arranger and administrative agent (the “Agent”) for the Lenders (as defined in the Credit Agreement referred to below), the Lenders party hereto, WABASH NATIONAL CORPORATION, a Delaware corporation (“Wabash”), certain Subsidiaries of Wabash designated on the signature pages hereto as borrowers (together with Wabash, such Subsidiaries are collectively referred as the “Borrowers”) and certain Subsidiaries of Wabash designated on the signature pages hereto as guarantors. Capitalized terms not otherwise defined herein have the definitions provided therefor in the Credit Agreement (as hereinafter defined).

…

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 13, 2026 by and between VELO3D, INC., a Delaware corporation (the “Company”), and THIENEMAN CONSTRUCTION, INC., an Indiana corporation (the “Holder”).

WHEREAS, the Company issued that certain Senior Secured Convertible Promissory Note (the “Promissory Note”) dated February 10, 2025, as amended on August 14, 2025 and March 4, 2026, in the principal amount of $10,000,000, payable to the Holder;

WHEREAS, on March 4, 2026, the Holder delivered a notice of conversion to the Company, for the conversion of $10,000,000 of principal amount of the Promissory Note, together with accrued and unpaid interest thereon, into 1,145,830 shares of common stock of the Company (the “Conversion Shares”); and

WHEREAS, pursuant to the terms of the Promissory Note, the parties hereto desire to enter into this Agreement in order to grant certain registration rights to the Holder as set forth below.

…

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 13, 2026 by and between VELO3D, INC., a Delaware corporation (the “Company”), and ARRAYED NOTES ACQUISITION CORP., a Delaware corporation (the “Holder”).

WHEREAS, the Company issued that certain Senior Secured Convertible Promissory Note (the “Promissory Note”) dated January 7, 2025, as amended on August 15, 2025 and March 4, 2026, in the principal amount of $5,000,000, payable to the Holder;

WHEREAS, on March 4, 2026, the Holder delivered a notice of conversion to the Company, for the conversion of $5,000,000 of principal amount of the Promissory Note, together with accrued and unpaid interest thereon, into 394,517 shares of common stock of the Company (the “Conversion Shares”); and

WHEREAS, pursuant to the terms of the Promissory Note, the parties hereto desire to enter into this Agreement in order to grant certain registration rights to the Holder as set forth below.

…

INDEPENDENT DIRECTOR AGREEMENT

THIS INDEPENDENT DIRECTOR AGREEMENT (this “Agreement”), is made effective as of July 8, 2026, and is by and between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and the undersigned (the “Director”).

RECITALS

A. The current Board consists of five members, two executive members and three independent members.

B. One of the Boards independent members has resigned

C. The Company desires to appoint the Director to serve on the Company’s board of directors (the “Board”) to replace the independent member that has resigned. The appointment will include membership on one or more committees of the Board, and the Director desires to accept such appointment to serve on the Board.

AGREEMENT

NOW THEREFORE, in consideration of the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Company and the Director hereby agree as follows:

…

RESTRICTED STOCK UNIT AGREEMENT

This Restricted Stock Unit Agreement (this “Agreement”) is made and entered into as of July 10, 2026 (the “Grant Date”) by and between Oncotelic Therapeutics, Inc., a Delaware corporation (the “Company”), and <____________________> (the “Holder”), with respect to the following facts:

A. In connection with the services rendered by the Holder to the Company or its affiliated entities, the Company shall grant to the Holder <__________> restricted stock units (the “RSUs”), each of which represents the right to receive, upon vesting and settlement, one (1) share of Series A Convertible Preferred Stock of the Company, par value $0.01 per share (the “Preferred Stock”), and which may be convertible into 1,000 shares of common stock, par value of $0.01, of the Company (“Common Stock”), subject to the terms and conditions of this Agreement.

…